A Phase 1/2 Trial of MG1 Maraba Expressing MAGE-A3 (MG1-MAGEA3), With Adenovirus Vaccine Expressing MAGE-A3 (Ad-MAGEA3), in Combination With Pembrolizumab in Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC)
This is a Phase 1/2, multi-centre, open-label, dose-escalation trial of Ad-MAGEA3 and
MG1-MAGEA3 in combination with pembrolizumab in patients with Non-Small Cell Lung Cancer who
have completed a first standard therapy with an platinum based chemotherapy.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society